AbbVie Expands Bid to Block Qulipta Copies With Two Patent Suits

Copies of the migraine drug Qulipta proposed by Hetero Labs Ltd. and MSN Laboratories Private Ltd. infringe four patents, AbbVie Inc. and its Allergan unit said in separate federal lawsuits.

The generic oral tablets in 10-, 30-, and 60-milligram dosages of atogepant, Qulipta’s active ingredient, infringe US Patent Nos. 12,090,148, 12,350,259, 12,383,545, and 12,465,598, according to complaints against Hetero and MSN filed Jan. 7 in the US District Court for the District of New Jersey. The patents cover methods of using atogepant to prevent migraines and dosing regimes for patients with liver or kidney issues and ...